A Promoter Methylation Pattern in the N-Methyl-d-Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma

Purpose: To investigate whether the promoter methylation pattern in N-methyl-d-aspartate receptor 2B (NMDAR2B) is correlated with clinical features of human esophageal squamous cell carcinoma (ESCC), the methylation status of the gene was examined at three different sites (P1, P2, and P3) where two CpG islands reside within 1 kb upstream of the transcription start site. Experimental Design: Three independent modalities for methylation analysis (bisulfite sequencing, combined bisulfite restriction analysis, and TaqMan methylation-specific PCR) were done to analyze total 67 ESCC tissues that included 43 primary tumors with well-characterized clinicopathologic variables including patient outcome. Results: Using an optimized cutoff value based on quantitative methylation-specific PCR, we found that patients with higher NMDAR2B methylation ratio in the proximal region (P1) showed a worse 5-year disease-specific survival rate than those without NMDAR2B methylation (P < 0.006). A significant correlation was also seen between NMDAR2B promoter methylation and the presence of vascular permeation (P = 0.03). Conclusion: NMDAR2B promoter methylation could be a clinically applicable marker in ESCC.

[1]  K. Mimori,et al.  A tumor-suppressive role for trypsin in human cancer progression. , 2003, Cancer research.

[2]  S. Snyder,et al.  Novel neural modulators. , 2003, Annual review of neuroscience.

[3]  L. Foroni,et al.  A Fluorescence in Situ Hybridization Map of 6 q Deletions in Acute Lymphocytic Leukemia : Identification and Analysis of a Candidate Tumor Suppressor Gene , 2004 .

[4]  H. Kuwano,et al.  Distinctive clinicopathological characteristics in esophageal squamous cell carcinoma. , 2003, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[5]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[6]  Lisa L. Smith,et al.  Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets , 2004, Cancer Research.

[7]  C. Croce,et al.  Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. , 2003, Cancer research.

[8]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[9]  M. Bear,et al.  Significance of N‐methyl‐d‐aspartate (NMDA) receptor‐mediated signaling in human keratinocytes , 2004, Journal of cellular physiology.

[10]  S. Groshen,et al.  Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[11]  M. Koike,et al.  Histopathologic characteristics of early stage esophageal carcinoma: A comparative study with gastric carcinoma , 2010, Cancer.

[12]  H. Messmann,et al.  Squamous cell cancer of the oesophagus. , 2001, Best practice & research. Clinical gastroenterology.

[13]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[14]  I. Weinstein,et al.  Amplification and expression of the human cyclin D gene in esophageal cancer. , 1992, Cancer research.

[15]  T. Giordano,et al.  Cloning of the cDNA for the human NMDA receptor NR2C subunit and its expression in the central nervous system and periphery. , 1996, Brain research. Molecular brain research.

[16]  R. Gossrau,et al.  Co-localization of nitric oxide synthase I (NOS I) and NMDA receptor subunit 1 (NMDAR-1) at the neuromuscular junction in rat and mouse skeletal muscle , 1997, Cell and Tissue Research.

[17]  W. Tan,et al.  Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. , 2003, Carcinogenesis.

[18]  G. Launoy,et al.  Oesophageal cancer in France: Potential importance of hot alcoholic drinks , 1997, International journal of cancer.

[19]  A. Carvalho,et al.  N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. , 2006, Cancer research.

[20]  Yoichi Tanaka,et al.  PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. , 2005, Cancer research.

[21]  Tsung-Teh Wu,et al.  Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  P. Hainaut,et al.  Molecular precursor lesions in oesophageal cancer. , 1998, Cancer surveys.

[23]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[24]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[25]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[26]  G. Yang,et al.  DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. , 2001, Carcinogenesis.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  L. Foroni,et al.  A Fluorescence in Situ Hybridization Map of 6q Deletions in Acute Lymphocytic Leukemia: Identification and Analysis of a Candidate Tumor Suppressor Gene , 2004 .

[29]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.